Kymera Therapeutics, Inc.
KYMR
$82.21
-$2.29-2.71%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -69.23M | -86.98M | -82.18M | -76.61M | -65.58M |
| Total Depreciation and Amortization | 2.02M | 2.03M | 2.15M | 2.08M | 2.05M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 13.28M | 12.41M | 17.47M | 13.30M | 11.71M |
| Change in Net Operating Assets | -34.91M | 5.79M | 35.45M | 1.35M | -27.33M |
| Cash from Operations | -88.84M | -66.75M | -27.11M | -59.88M | -79.15M |
| Capital Expenditure | -434.00K | -106.00K | -181.00K | -695.00K | -467.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -142.41M | -394.29M | -235.12M | 60.72M | 49.08M |
| Cash from Investing | -142.84M | -394.40M | -235.30M | 60.02M | 48.62M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -425.00K | -416.00K | -419.00K | -382.00K | -277.00K |
| Issuance of Common Stock | 19.19M | 757.54M | 39.93M | 246.11M | 535.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -51.90M | -- | -- | -- |
| Cash from Financing | 18.77M | 705.22M | 39.51M | 245.73M | 258.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -212.91M | 244.07M | -222.90M | 245.86M | -30.28M |